164P Current use of breast cancer multigene signatures in clinical practice among European experts: Results from the PROCURE Project

BackgroundSeveral Breast Cancer Multigene Signatures (BCMS) are available to profile early breast cancer (eBC) but knowledge regarding their use in clinical practice is scarce. Results from the European PROCURE Project on of BCMS current daily presented.MethodsA Delphi questionnaire drafted by Scientific Committee was administered twice 133 experts 11 countries. The included 5 sections: 1) Panellists’ and experience with BCMS, 2) Current eBC 3) opinion utility according patient profiles, 4) Agreement a set recommendations 5) Identification unmet needs future applications BCMS.Results85.0% panellists reported existence hospital/country policies regulate being nodal status (92.0%), HER2 negative ICH/FISH/CISH (87.6%) tumour size (77.87%) most important criteria defined those guidelines for BCMS. When not available, main criterion still (80.0%), they also give great importance menopausal percentage Ki67 expression (70.0%). Also, two reasons using patients were assess risk distant recurrence within 10 years order avoid chemotherapy (60.2%) predict benefit (46.6%). Finally, define prognosis treatment needs, used routinely or selected more than 60% participants, regardless patient’s gender age, similar results when asked status; lack lymph node involvement (97.0%) 1–3 nodes (88.0%); HR-positive (98.5%); HER2-negative (96.2%).ConclusionsThe reason benefit. This, along fact that some 4 positive node, triple HER2+ patients, suggests there need education how correctly interpreting results.Editorial acknowledgementEditorial writing assistance has been provided Adelphi Targis, S.L.Legal entity responsible studyVeracyte Inc.FundingVeracyte Inc.DisclosureG. Curigliano: Financial Interests, Personal, Invited Speaker: Roche , AstraZeneca Daiichi Sankyo, Novartis Pfizer Pfizer; Advisory Board: Ellipsis, Lilly Veracyte, BMS Merck Exact Sciences; Board, Science, Celcuity; Institutional, Research Grant, Investigator Initiated Trial: Merck; Funding, Phase I studies: Blueprint Medicine, Kymab, Astellas Sanofi Philogen; Speaker, basket trial: Relay Therapeutics; Non-Financial Officer, Italian National Health Council as Advisor Ministry Health: Consiglio Superiore di Sanità; Role, Member Council. Patient advocacy association: Europa Donna; Foundation: Fondazione Beretta; No compensation this role. This public national company prevention: Lega Italiana Lotta ai Tumori; Council: EUSOMA. F. Cardoso: Other, Consultancy: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, Prime Roche, Sanofi, Samsung Bioepis, Seagen, Teva; Boehringer-Ingelheim, Bristol-Myers-Squibb, Bayer, Daiichi, Fresenius GmbH, Ipsen, Incyte, Nektar Therapeutics, Nerviano, Medigene, MedImmune, Merck, Millenium, Sanofi-Aventis, Sonus, Taiho Tesaro, Tigris, Wilex, Wyeth; Leadership President: ABC Global Alliance Consensus Conference Guidelines; Member: ESMO, ESO, EORTC, BCG, IBCSG, SOLTI, ASCO, AACR, EACR, SIS, ASPIC. M.I. Gnant: PierreFabre; DaiichiSankyo, EliLilly; Consulting scientific matters: LifeBrain; Expert Testimony: Veracyte; Full part-time Employment: ABCSG GmbH; Spouse employed Sandoz: Sandoz. N. Harbeck: MSD Pierre Fabre Art Tempi, Onkowissen, Gilead Sandoz-Hexal, Aptitude Health, Sanofi; Husband: WSG (Husband); Ownership Interest: West German Study Group; Funding: Palleos, TRIO, WSG; Member, AGO Guideline Committee: Committee; Educational Programs: ESO /ESCO; Founding Editor: BreastCare Journal. J. King: Role: Gilead, Lilly; Speaker’s Bureau: Novartis. A. Laenkholm: Commttee member: MSD; . Penault-Llorca: Other: AbbVie, Agendia, Astellas, BMS, Sciences, GSK, Janssen, Lilly, Life, MSD, Myriad, Servier, Veracyte. Prat: Lecture fees: Amgen Nanostring Technologies, Sankyo; Puma, Oncolytics Biotech Guardan Peptomyc, Reveal Genomics, SL; Contracted research: Boehringer, Nanostring, Sysmex Medica Scientia inno. Research, SL, Celgene Pzifer; technologies; Clinical trials: Executive boards: SOLTI cooperative group; Patronage committee: Foundation, Actitud Frente al Cáncer Foundation; presented. Several MethodsA A Results85.0% (96.2%). 85.0% ConclusionsThe results.